NO309653B1 - Autiogeneseinhiberende pyridazinaminer - Google Patents

Autiogeneseinhiberende pyridazinaminer Download PDF

Info

Publication number
NO309653B1
NO309653B1 NO982037A NO982037A NO309653B1 NO 309653 B1 NO309653 B1 NO 309653B1 NO 982037 A NO982037 A NO 982037A NO 982037 A NO982037 A NO 982037A NO 309653 B1 NO309653 B1 NO 309653B1
Authority
NO
Norway
Prior art keywords
formula
alkyl
phenyl
alk
compounds
Prior art date
Application number
NO982037A
Other languages
English (en)
Norwegian (no)
Other versions
NO982037D0 (no
NO982037L (no
Inventor
Raymond Antoine Stokbroekx
Marcel Jozef Maria Van Der Aa
Marc Willems
Lieven Meerpoel
Marcel Gerebernus Maria Luyckx
Robert W Tuman
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of NO982037D0 publication Critical patent/NO982037D0/no
Publication of NO982037L publication Critical patent/NO982037L/no
Publication of NO309653B1 publication Critical patent/NO309653B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
NO982037A 1996-01-15 1998-05-05 Autiogeneseinhiberende pyridazinaminer NO309653B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP96200085 1996-01-15
PCT/EP1997/000201 WO1997026258A1 (en) 1996-01-15 1997-01-14 Angiogenesis inhibiting pyridazinamines

Publications (3)

Publication Number Publication Date
NO982037D0 NO982037D0 (no) 1998-05-05
NO982037L NO982037L (no) 1998-09-15
NO309653B1 true NO309653B1 (no) 2001-03-05

Family

ID=8223585

Family Applications (1)

Application Number Title Priority Date Filing Date
NO982037A NO309653B1 (no) 1996-01-15 1998-05-05 Autiogeneseinhiberende pyridazinaminer

Country Status (21)

Country Link
US (1) US5985878A (da)
EP (1) EP0876366B1 (da)
JP (1) JP4169368B2 (da)
KR (1) KR100443893B1 (da)
CN (1) CN1104430C (da)
AT (1) ATE203534T1 (da)
AU (1) AU717744B2 (da)
CA (1) CA2237273C (da)
DE (1) DE69705819T2 (da)
DK (1) DK0876366T3 (da)
ES (1) ES2162235T3 (da)
GR (1) GR3036900T3 (da)
IL (1) IL124461A (da)
MY (1) MY117098A (da)
NO (1) NO309653B1 (da)
NZ (1) NZ326354A (da)
PT (1) PT876366E (da)
SI (1) SI0876366T1 (da)
TW (1) TW480256B (da)
WO (1) WO1997026258A1 (da)
ZA (1) ZA97288B (da)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6228871B1 (en) 1995-07-10 2001-05-08 Merck & Co., Inc. Angiogenesis inhibitors
CO4950519A1 (es) * 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
WO1998051662A2 (en) 1997-05-14 1998-11-19 Atherogenics, Inc. Compounds and methods for the inhibition of the expression of vcam-1
US6852878B2 (en) 1998-05-14 2005-02-08 Atherogenics, Inc. Thioketals and thioethers for inhibiting the expression of VCAM-1
US6670398B2 (en) 1997-05-14 2003-12-30 Atherogenics, Inc. Compounds and methods for treating transplant rejection
ID24231A (id) * 1997-06-24 2000-07-13 Janssen Pharmaceutica Nv Derivat-derivat 5-disubstitusi-1,2,4-tiadiazolil yang menghambat angiogenesis
US6833369B2 (en) 1997-06-24 2004-12-21 Janssen Pharmaceutica, Nv Angiogenesis inhibiting 5-substituted-1,2,4,-thiadiazolyl derivatives
IL133652A (en) * 1997-06-24 2003-04-10 Janssen Pharmaceutica Nv Angiogenesis inhibiting thiadiazolyl pyridazine derivatives, their preparation and pharmaceutical compositions comprising them
KR100523755B1 (ko) 1997-06-24 2005-10-26 얀센 파마슈티카 엔.브이. 혈관형성을 저해하는 티아디아졸릴 피리다진 유도체
US6465484B1 (en) 1997-09-26 2002-10-15 Merck & Co., Inc. Angiogenesis inhibitors
US6162804A (en) * 1997-09-26 2000-12-19 Merck & Co., Inc. Tyrosine kinase inhibitors
AR013693A1 (es) * 1997-10-23 2001-01-10 Uriach & Cia Sa J Nuevas piperidinas y piperazinas como inhibidores de la agregacion plaquetaria
ATE278670T1 (de) * 1997-10-27 2004-10-15 Neurosearch As Heteroaryl diazacycloalkane als cholinergische ligande für nikotin-acetylcholin-rezeptoren
AU1600599A (en) * 1998-02-27 1999-09-15 Warner-Lambert Company Heterocyclic substituted aniline calcium channel blockers
US7265115B2 (en) 1999-01-29 2007-09-04 Abbott Laboratories Diazabicyclic CNS active agents
US6833370B1 (en) * 1999-05-21 2004-12-21 Abbott Laboratories Heterocycle substituted aminoazacycles useful as central nervous system agents
US6887870B1 (en) * 1999-10-12 2005-05-03 Bristol-Myers Squibb Company Heterocyclic sodium/proton exchange inhibitors and method
MXPA02007035A (es) * 2000-01-20 2002-12-13 Eisai Co Ltd Compuesto ciclico conteniendo nitrogeno y composicion farmaceutica conteniendo el compuesto.
IT1316986B1 (it) 2000-01-25 2003-05-26 Sigma Tau Ind Farmaceuti Derivati glicosamminoglicani parzialmente desolfatati nonanticoagulanti ad attivita' antiangiogenica.
AU2001253401B2 (en) 2000-04-11 2006-12-07 Atherogenics, Inc Compounds and methods to increase plasma hdl cholesterol levels and improve hdl functionality
US7208503B2 (en) 2000-04-21 2007-04-24 Janssen Pharmaceutica N.V. Angiogenesis inhibiting 5-substituted-1,2,4-thiadiazolyl derivatives
MXPA02011319A (es) * 2000-05-15 2003-06-06 Pharma Mar Sa Analogos antitumorales de ecteinascidina 743.
GB0111078D0 (en) 2001-05-04 2001-06-27 Novartis Ag Organic compounds
US20050119251A1 (en) * 2001-12-21 2005-06-02 Jian-Min Fu Nicotinamide derivatives and their use as therapeutic agents
US7390813B1 (en) 2001-12-21 2008-06-24 Xenon Pharmaceuticals Inc. Pyridylpiperazines and aminonicotinamides and their use as therapeutic agents
TWI345974B (en) * 2003-07-30 2011-08-01 Xenon Pharmaceuticals Inc Pyridazine derivatives and their use in the inhibition of stearoyl-coa desaturase
US7754711B2 (en) * 2003-07-30 2010-07-13 Xenon Pharmaceuticals Inc. Pyridazine derivatives and their use as therapeutic agents
US20050065178A1 (en) * 2003-09-19 2005-03-24 Anwer Basha Substituted diazabicycloakane derivatives
US7319108B2 (en) 2004-01-25 2008-01-15 Sanofi-Aventis Deutschland Gmbh Aryl-substituted heterocycles, process for their preparation and their use as medicaments
DE102004003812A1 (de) * 2004-01-25 2005-08-11 Aventis Pharma Deutschland Gmbh Arylsubstituierte Heterozyklen, Verfahren ihrer Herstellung und ihre Verwendung als Arzneimittel
WO2005080378A1 (ja) * 2004-02-24 2005-09-01 Mitsubishi Pharma Corporation 縮合ピリダジン誘導体
TW200626155A (en) 2004-09-20 2006-08-01 Xenon Pharmaceuticals Inc Heterocyclic derivatives and their use as therapeutic agents
JP4958785B2 (ja) * 2004-09-20 2012-06-20 ゼノン・ファーマシューティカルズ・インコーポレイテッド 複素環誘導体およびステアロイル−ＣｏＡデサチュラーゼインヒビターとしてのそれらの使用
CN101084211A (zh) 2004-09-20 2007-12-05 泽农医药公司 杂环衍生物及其作为治疗剂的用途
CA2580855A1 (en) * 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
ES2359840T5 (es) * 2004-09-20 2015-03-25 Xenon Pharmaceuticals Inc. Derivados de piridina para inhibición de estearoil-CoA-desaturasa humana
BRPI0515483A (pt) 2004-09-20 2008-07-22 Xenon Pharmaceuticals Inc derivados heterocìclicos para o tratamento de doenças mediadas por enzimas estearoil-coa desaturase
WO2006034441A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
AU2005286728A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as mediators of stearoyl-CoA desaturase
WO2006071875A1 (en) 2004-12-29 2006-07-06 Millennium Pharmaceuticals, Inc. Compounds useful as chemokine receptor antagonists
US7635698B2 (en) 2004-12-29 2009-12-22 Millennium Pharmaceuticals, Inc. Compounds useful as chemokine receptor antagonists
CA2598456A1 (en) * 2005-02-16 2006-08-24 Schering Corporation Heterocyclic substituted piperazines with cxcr3 antagonist activity
WO2007046867A2 (en) * 2005-05-19 2007-04-26 Xenon Pharmaceuticals Inc. Piperidine derivatives and their uses as therapeutic agents
WO2007130075A1 (en) 2005-06-03 2007-11-15 Xenon Pharmaceuticals Inc. Aminothiazole derivatives as human stearoyl-coa desaturase inhibitors
EP1910352A1 (en) * 2005-07-20 2008-04-16 Merck Frosst Canada Ltd. Heteroaromatic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase
AU2006326815A1 (en) * 2005-12-20 2007-06-28 Merck Frosst Canada Ltd. Heteroaromatic compounds as inhibitors of stearoyl-coenzyme A delta-9 desaturase
TW200826936A (en) 2006-12-01 2008-07-01 Merck Frosst Canada Ltd Azacycloalkane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase
AR064965A1 (es) 2007-01-26 2009-05-06 Merck Frosst Canada Inc Derivados de azacicloalcanos como inhibidores de estearoil - coenzima a delta -9 desaturasa
US8252840B2 (en) 2007-03-26 2012-08-28 Salutria Pharmaceuticals Llc Methods of derivatives of probucol for the treatment of type II diabetes
WO2009055077A1 (en) 2007-10-25 2009-04-30 Exelixis, Inc. Tropane compounds
EA201071248A1 (ru) 2008-04-29 2011-06-30 Эли Лилли Энд Компани Дизамещенные фталазиновые антагонисты пути hedgehog
HRP20130527T1 (en) 2008-11-03 2013-07-31 Eli Lilly And Company Disubstituted phthalazine hedgehog pathway antagonists
CA2743264C (en) 2008-11-17 2014-02-18 Julia Marie Clay Tetrasubstituted pyridazines hedgehog pathway antagonists
CA2743483C (en) 2008-11-17 2014-03-11 Eli Lilly And Company Tetrasubstituted pyridazine hedgehog pathway antagonists
AR077014A1 (es) 2009-06-19 2011-07-27 Lilly Co Eli Compuesto derivado de ftalazina 1,4-disustituida, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para el tratamiento de cancer
WO2011002067A1 (ja) * 2009-07-02 2011-01-06 武田薬品工業株式会社 複素環化合物およびその用途
US9102669B2 (en) 2011-12-06 2015-08-11 Janssen Pharmaceutica Nv Substituted piperidinyl-pyridazinyl derivatives useful as SCD 1 inhibitors
WO2013085954A1 (en) 2011-12-06 2013-06-13 Janssen Pharmaceutica Nv Substituted piperidinyl-carboxamide derivatives useful as scd 1 inhibitors
GB201309508D0 (en) 2013-05-28 2013-07-10 Redx Pharma Ltd Compounds
GB201311953D0 (en) * 2013-07-03 2013-08-14 Redx Pharma Ltd Compounds
RS63124B1 (sr) 2018-03-08 2022-05-31 Incyte Corp Aminopirazin diol jedinjenja kao pi3k-y inhibitori
US11046658B2 (en) 2018-07-02 2021-06-29 Incyte Corporation Aminopyrazine derivatives as PI3K-γ inhibitors
CN108912116A (zh) * 2018-08-15 2018-11-30 翟学旭 一种含氮杂环类衍生物及其在视网膜疾病中的应用
JP2023546536A (ja) 2020-10-13 2023-11-02 エンデバー バイオメディシンズ， インコーポレイテッド 線維症を処置する方法
US20250333397A1 (en) * 2021-08-30 2025-10-30 Remix Therapeutics Inc. Compounds and methods for modulating splicing
GB202202297D0 (en) 2022-02-21 2022-04-06 Verona Pharma Plc Formulation production process
US12194045B1 (en) 2023-06-26 2025-01-14 Verona Pharma Plc Particulate composition
WO2025188802A1 (en) 2024-03-05 2025-09-12 Endeavor Biomedicines, Inc. Methods of improving lung function

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5001125A (en) * 1984-03-26 1991-03-19 Janssen Pharmaceutica N.V. Anti-virally active pyridazinamines
US4992433A (en) * 1987-11-23 1991-02-12 Janssen Pharmaceutica N.V. Novel pyridazinamine derivatives
FR2663326B2 (fr) * 1989-11-17 1992-10-16 Sanofi Sa Derives de la pyridazine, procede de preparation et compositions pharmaceutiques en contenant.
US5461053A (en) * 1989-02-07 1995-10-24 Sanofi Pyridazine derivatives
NZ233526A (en) * 1989-05-15 1991-09-25 Janssen Pharmaceutica Nv Pyridazine derivatives and their pharmaceutical compositions
GB8911158D0 (en) * 1989-05-16 1989-07-05 Janssen Pharmaceutica Nv Antiviral pyridazinamines
JO1645B1 (en) * 1989-12-26 1991-11-27 شركة جانسين فارماسوتيكا ان. في Pyridazine compounds are antibacterial viruses
ZA9010357B (en) * 1989-12-26 1992-08-26 Janssen Pharmaceutica Nv Antipicornaviral pyridazinamines
US5100893A (en) * 1990-04-18 1992-03-31 Janssen Pharmaceutica N.V. Antipicornaviral pyridazinamines
US5242924A (en) * 1992-07-02 1993-09-07 Sterling Winthrop Inc. Tetrazolyl-(phenoxy and phenoxyalkyl)-piperidinylpyridazines as antiviral agents

Also Published As

Publication number Publication date
TW480256B (en) 2002-03-21
CA2237273A1 (en) 1997-07-24
ZA97288B (en) 1998-07-14
JP4169368B2 (ja) 2008-10-22
SI0876366T1 (en) 2001-12-31
ES2162235T3 (es) 2001-12-16
US5985878A (en) 1999-11-16
JP2000503014A (ja) 2000-03-14
DE69705819D1 (de) 2001-08-30
DK0876366T3 (da) 2001-11-05
EP0876366A2 (en) 1998-11-11
ATE203534T1 (de) 2001-08-15
GR3036900T3 (en) 2002-01-31
CN1104430C (zh) 2003-04-02
DE69705819T2 (de) 2002-04-11
PT876366E (pt) 2002-01-30
KR19990067654A (ko) 1999-08-25
KR100443893B1 (ko) 2004-10-15
IL124461A0 (en) 1998-12-06
CN1208415A (zh) 1999-02-17
AU717744B2 (en) 2000-03-30
NO982037D0 (no) 1998-05-05
EP0876366B1 (en) 2001-07-25
AU1443997A (en) 1997-08-11
IL124461A (en) 2000-07-26
NZ326354A (en) 1999-05-28
NO982037L (no) 1998-09-15
CA2237273C (en) 2009-01-13
MY117098A (en) 2004-05-31
WO1997026258A1 (en) 1997-07-24

Similar Documents

Publication Publication Date Title
NO309653B1 (no) Autiogeneseinhiberende pyridazinaminer
AU2001234175B2 (en) Novel cyclic amide derivatives
CA2934788C (en) Bicyclic heterocyclic derivatives as bromodomain inhibitors
WO1999031062A1 (en) Novel pyridine compounds
JPWO2003026661A1 (ja) インスリン分泌促進剤及び新規なピリミジン誘導体
WO2015057626A1 (en) QUINOLINYL MODULATORS OF RORyT
SK280812B6 (sk) 1,3-substituované cykloalkány a 1,3-substituované cykloalkény, spôsoby ich prípravy a farmaceutické prípravky na ich báze
AU2009266001B2 (en) Substituted 6- (1-piperazinyl) -pyridazines as 5-HT6 receptor antagonists
US5670522A (en) Dopamine receptor subtype ligands
AU2021410119A1 (en) Tetrahydroquinoline derivative and medicinal use thereof
JP7104783B2 (ja) ムスカリンｍ１受容体陽性アロステリックモジュレーターであるヘテロアリール化合物
US4988699A (en) Substituted tetrahydrobenzothiazoles as dopaminergic agents
CZ2002499A3 (cs) Derivát piperidinalkoholu, způsob jeho přípravy, jeho pouľití a farmaceutický prostředek, který ho obsahuje
JP6626885B2 (ja) 新しいピリジニルオキシ及びフェニルオキシピラゾリル化合物
JP6670832B2 (ja) アルドステロン合成酵素阻害剤としての新規ジヒドロキノリンピラゾリル化合物
US4906642A (en) Pyridine derivatives
TW200410965A (en) Compounds
JP6669734B2 (ja) ピラゾリル−３，４−ジドヒドロキノリン−２−オン・アルドステロン合成酵素阻害剤
JP6622300B2 (ja) 新規なジヒドロキノリンピラゾリル化合物
CA3256001A1 (en) THERAPEUTIC OR PROPHYLACTIC AGENT FOR AMYOTROPHIC LATERAL SCLEROSIS
HK1233250B (zh) 新的吡啶基氧基-和苯基氧基-吡唑基化合物